SR0119LRB103 31105 LAW 57766 r

1
SENATE RESOLUTION

 
2    WHEREAS, Many people with serious mental health
3conditions, such as bipolar disorder, major depression,
4schizophrenia, and schizoaffective disorder, or
5gastrointestinal disorders, including gastroparesis, nausea,
6and vomiting, may be treated with medications that work as
7dopamine receptor blocking agents (DRBAs), including
8antipsychotics; and
 
9    WHEREAS, While ongoing treatment with these medications
10can be necessary, prolonged use can also lead to tardive
11dyskinesia (TD), an involuntary movement disorder that is
12characterized by uncontrollable, abnormal, and repetitive
13movements of the face, torso, and/or other body parts; and
 
14    WHEREAS, It is estimated that TD affects approximately
15600,000 people in the United States, and approximately 70% of
16people with TD have not been diagnosed, making it important to
17raise awareness about the symptoms and impact of TD because
18even mild symptoms of TD can have physical, social, and
19emotional consequences; and
 
20    WHEREAS, It is important for people taking DRBA medication
21to be monitored for TD; regular screening for TD in these
22patients is recommended by the American Psychiatric

 

 

SR0119- 2 -LRB103 31105 LAW 57766 r

1Association (APA); and
 
2    WHEREAS, Clinical research has led to the availability of
3two treatments for adults with TD by the U.S. Food and Drug
4Administration; and
 
5    WHEREAS, The Legislature can raise awareness of Tardive
6Dyskinesia in the public and in the medical community;
7therefore, be it
 
8    RESOLVED, BY THE SENATE OF THE ONE HUNDRED THIRD GENERAL
9ASSEMBLY OF THE STATE OF ILLINOIS, that we declare May 1
10through May 7, 2023 as Tardive Dyskinesia Awareness Week in
11the State of Illinois; and be it further
 
12    RESOLVED, That we encourage the citizens of Illinois to
13become better informed about Tardive Dyskinesia.